Equities

Eurofins-Cerep SA

ALECR:PAR

Eurofins-Cerep SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)21,400.00
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024 13:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8.63131.30
Total Receivables, Net544244
Total Inventory3.834.102.82
Prepaid expenses0.150.100.41
Other current assets, total0.150.320.10
Total current assets665948
Property, plant & equipment, net109.738.86
Goodwill, net2.232.232.23
Intangibles, net0.000.000.00
Long term investments0.020.020.02
Note receivable - long term0.240.240.24
Other long term assets--0--
Total assets797160
LIABILITIES
Accounts payable3.554.614.48
Accrued expenses3.834.003.70
Notes payable/short-term debt0.000.000.02
Current portion long-term debt/capital leases------
Other current liabilities, total5.473.834.12
Total current liabilities131212
Total long term debt000
Total debt0.000.000.02
Deferred income tax------
Minority interest------
Other liabilities, total1.781.672.04
Total liabilities151414
SHAREHOLDERS EQUITY
Common stock0.080.080.08
Additional paid-in capital111111
Retained earnings (accumulated deficit)544634
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity655745
Total liabilities & shareholders' equity797160
Total common shares outstanding0.010.010.01
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.